BioSpace

Shionogi makes $2B rare disease play with IntraBio buy

With its acquisition of IntraBio, Shionogi will gain ownership over Aqneursa, which could hit peak global sales of $1 billion across its two indications in Niemann-Pick disease type C and ataxia-telangiectasia, according to Jefferies.

By BioSpace

1 min read
Shionogi makes $2B rare disease play with IntraBio buy
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights